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Abstract
Introduction Dysfunction of brain dopamine systems is
involved in various neuropsychiatric disorders. Challenge
studies with dopamine receptor agonists have been per-
formed to assess dopamine receptor functioning, classically
using the release of growth hormone (GH) from the
hindbrain as primary outcome measure. The objective of
the current study was to assess dopamine receptor func-
tioning at the forebrain level.
Methods Fifteen healthy male volunteers received apomor-
phine sublingually (2 mg), subcutaneously (0.005 mg/kg),
and placebo in a balanced, double-blind, cross-over design.
Outcome measures were plasma GH levels, performance on
an AX continuous performance test, and prepulse inhibition
of the acoustic startle. The relation between central
outcome measures and apomorphine levels observed in
plasma and calculated in the brain was modeled using a
two-compartmental pharmacokinetic-pharmacodynamic
analysis.
Results After administration of apomorphine, plasma GH
increased and performance on the AX continuous perfor-
mance test deteriorated, particularly in participants with low
baseline performance. Apomorphine disrupted prepulse
inhibition (PPI) on high-intensity (85 dB) prepulse trials
and improved PPI on low intensity (75 dB) prepulse trials,
particularly in participants with low baseline PPI. High
cognitive performance at baseline was associated with
reduced baseline sensorimotor gating. Neurophysiological
measures correlated best with calculated brain apomorphine
levels after subcutaneous administration.
Conclusion The apomorphine challenge test appears a
useful tool to assess dopamine receptor functioning at the
forebrain level. Modulation of the effect of apomorphine by
baseline performance levels may be explained by an inverted
U-shape relation between prefrontal dopamine functioning
and cognitive performance, and mesolimbic dopamine
functioning and sensorimotor gating. Future apomorphine
challenge tests preferentially use multiple outcome measures,
after subcutaneous administration of apomorphine.
Keywords Dopamine.Apomorphine.Cognition.Prepulse
inhibition.Neuroendocrine
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Dysfunctioning of dopaminergic neurocircuitry has been
implicated in various neuropsychiatric disorders including
substance dependence, Tourette's syndrome, schizophrenia,
and others (see (Kienast and Heinz 2006) for a compre-
hensive review). Pharmacological challenge tests using
dopamine receptor agonists provide a useful tool for
investigating sensitivity of brain dopamine receptors.
Classically, the release of growth hormone (GH) after
administration of a dopamine agonist, e.g., apomorphine
(APO) or bromocriptine has been used to assess central
dopamine sensitivity, showing reduced plasma GH levels in
patients suffering from alcohol dependence, major depres-
sion, and schizophrenia (Duval et al. 2000; Mokrani et al.
1995; Schmidt et al. 2001).
The GH response to APO is mediated by dopamine
receptors in the hindbrain (pituitary) region, whereas
prefrontal and mesolimbic dopamine neurotransmission
are more relevant for human behavior and neuropsychiatric
disorders (Meister et al. 1985; Seema0n and Van Tol 1993).
This report describes a dopamine challenge in healthy
human volunteers, using three indices of dopamine func-
tion: plasma GH levels, performance on a continuous
performance test, and prepulse inhibition of the acoustic
startle response.
Dopamine is involved in cognitive functioning, includ-
ing perceptual speed (spatial), working memory, and
response inhibition (Backman et al. 2000; Cropley et al.
2006; Reeves et al. 2005). Deficits in cognitive perfor-
mance on various cognitive tasks have been described in
disorders with a decrease in prefrontal dopamine function-
ing such as attention-deficit hyperactivity disorder (ADHD)
and schizophrenia (Iversen and Iversen 2007). Evidence
from both animal and human studies, using pharmacolog-
ical stimulation of dopamine receptors, suggests that both
too little and too much stimulation of dopamine impairs
cognitive performance (Cools 2008; Gibbs and D'Esposito
2005; Vijayraghavan et al. 2007).
Individuals with poor baseline performance on an n-back
task, with presumed suboptimal prefrontal dopamine
functioning, improved after administration of the dopamine
agonist D-amphetamine, whereas individuals with high
baseline performance deteriorated (Mattay et al. 2000;
Mattay et al. 2003). Using the dopamine agonist bromo-
criptine, similar findings have been found on a variety of
cognitive tasks including the Wisonsin Card Sorting Task
(set shifting task), the Stroop task (interference task), and
Corsi Block Tapping Task (spatial span task) (Kimberg
et al. 1997b; Mehta et al. 2001).
In addition, amphetamine improved performance on a
continuous performance task in individuals scoring low on
novelty seeking with presumed low levels of dopamine and
impaired performance in individuals scoring high on
novelty seeking with presumed high dopamine levels
(Fleming et al. 1995). Thus, a specific level of dopamine
appears necessary for optimal functioning of the prefrontal
cortex following an inverted U-dose-response curve (Gibbs
and D'Esposito 2005; Swainson et al. 2000; Vijayraghavan
et al. 2007; Zahrt et al. 1997).
Administration of the dopamine agonist APO has been
shown to disrupt performance on a working memory task in
healthy human volunteers, probably by altered brain
activity in the dorsolateral prefrontal cortex (Fletcher et al.
1996; Friston et al. 1992; Grasby et al. 1993). We selected
the AX continuous performance test (AX-CPT) because
previous pharmacological studies with dopaminergic med-
ication (apomorphine and cabergoline) have shown clear
effects on task performance using this task (Frank and
O'Reilly 2006; Schellekens et al. 2009). We hypothesized
that administration of APO to healthy controls would
change task performance, depending on baseline task
performance, such that performance improves in those
subjects with low baseline performance and deteriorates in
those with high baseline performance.
Prepulse inhibition (PPI), the phenomenon that a startle
response elicited by a sudden intense stimulus (noise burst)
is inhibited, when it is preceded by a weaker stimulus, has
also been shown to be related to dopamine functioning.
Reductions of PPI have been shown in disorders in which
an increase in dopamine functioning has been hypothe-
sized, such as schizophrenia, obsessive compulsive disor-
der, and tic disorder (see Braff et al. 2001 for a review on
PPI paradigms in humans). Moreover, dopamine agonists
have been shown to reduce PPI in animals and humans (see
for further reviews: Braff et al. 2001, Swerdlow et al. 2000;
Swerdlow et al. 2001a, b). An inverted-U association
between PPI levels and dopamine functioning has been
hypothesized, since the disruptive effects of the dopamine
agonist pergolide and amantadine on PPI in humans have
been shown only in subjects with high baseline PPI levels,
suggesting excessive dopaminergic stimulation in subjects
with high levels of baseline PPI (Bitsios et al. 2005; Talledo
et al. 2009b).
Although the neuronal circuitry underlying PPI is
extensive, there is a large amount of evidence indicating
that the APO-induced deficit in PPI depends predominantly
on stimulation of mesolimbic dopamine receptors in the
nucleus accumbens (Swerdlow et al. 2000; Swerdlow et al.
2001a, b). We expected administration of APO to change
PPI, depending on baseline levels of PPI, such that PPI
increases in those subjects with low baseline PPI and
reduces in those with high baseline PPI.
The relationship between APO levels in blood, brain,
and GH release was first explored by Aymard et al. (2003).
They showed that APO levels in the second compartment
560 Psychopharmacology (2010) 207:559–569(i.e., the concentration of APO in cerebrospinal fluid; CSF),
correlated better with plasma GH levels than APO levels in
the first compartment (i.e., the concentration of APO in
plasma) (Aymard et al. 2003; Hofstee et al. 1994). As
shown by Hofstee et al. (1994), APO levels in CSF can be
reliably calculated from plasma APO concentrations using
pharmacokinetic modeling (Hofstee et al. 1994). We
measured plasma APO levels and calculated APO levels
in the CSF and hypothesized that central effects of APO
can best be modeled using calculated APO levels in the
CSF compared to observed APO levels in the plasma. We
used both subcutaneous (s.c.) and sublingual (s.l.) admin-
istration of APO in order to be able to model the central
effect of APO in different kinetic profiles and to assess
which mode of administration was most appropriate for use
in a challenge test.
Methods and materials
Design
A double-blind, placebo-controlled challenge study was
performed in 15 healthy males using a balanced, cross-
over design with three treatment conditions in a double-
dummy approach: APO 2 mg s.l./placebo s.c., APO
0.005 mg/kg s.c./placebo s.l., and placebo s.l./s.c.. Low
doses of APO were used because of poor tolerability at
higher doses (nausea, vomiting, and collapse, unpublished
pilot studies). The study protocol was approved by the
regional ethical board.
Participants
Participants were recruited through advertisements in
regional newspapers and at the campus of Radboud
University Nijmegen. After written informed consent,
participants were screened for any medical condition,
including laboratory abnormalities and the use of medica-
tion or drugs within 2 months prior to the study. Auditory
acuity was evaluated during medical examination by use of
tuning fork tests (Weber, Rinne, and Swabach) and whisper
tests.
Psychiatric history was assessed using the Dutch version
of the Mini International Neuropsychiatric Interview for
psychiatric disorders version 2.1 and the Dutch version of
the ADHD rating scale (Sandra Kooij et al. 2008; Sheehan
et al. 1998; van Vliet and de Beurs 2007). To assess history
of drug and alcohol use, we used the Dutch version of the
Addiction Severity Index, Section 4 (Langeland et al. 2001;
McLellan et al. 1992). Participants with any psychiatric
(family) history including substance use disorders and
habitual smoking (daily nicotine use) were excluded. Out
of 16 screened individuals, 15 were eligible, mean age (SD)
25.2 (5.9) years. Participants were not allowed to smoke or
use caffeine during study mornings, or take alcohol 2 days
before study days.
Measurements
Plasma apomorphine and growth hormone levels
To assess plasma APO and GH levels, blood (4 ml) was
taken. After centrifugation, 2.0-ml samples were kept on ice
and stored at −30˚C. APO levels were assessed by high-
pressure liquid chromatography with electrochemical de-
tection (Essink et al. 1991). GH levels were assessed by
radio immuno assay, using antiserum raised in guinea pig.
The first (80/505) international standard for GH was used
for the standard curve with a detection limit of 1.6 mIU/L.
Two participants with baseline GH levels >10 U/l were
excluded from analysis. Plasma APO levels were available
for nine of 15 individuals due to contamination of the
antioxidant in one series of batches.
AX continuous performance task
In the AX continuous performance task (AX-CPT), single
white letters were consecutively shown on a black screen
(interstimulus interval = 1,300 ms). Participants were
instructed to give a target response (right button press)
after the probe "X", if preceded by a cue "A", or a non-
target response (left button press) after any other combina-
tion of letters (van der Linden et al. 2006). To increase task
difficulty, two distracter letters were presented between cue
and probe (van der Linden et al. 2006). To increase
sensitivity for impulsive response styles (commission
errors), 70% were target trials (Braver et al. 2001).
Responses were scored in a window between 100 and
2,000 ms after stimulus onset. Performance during each
session was calculated as the mean reaction time and
accuracy on AX trials (the percentage commission errors).
Non responses (omissions) were not taken into account
given the low number (<1%). A median split on baseline
accuracy was used to divide high and low baseline
performers (Kimberg et al. 1997a).
Prepulse inhibition
Reflex eyeblink responses were measured as electromyo-
graphic activity over the right orbicularis oculi muscle with
a sampling frequency of 1,000 Hz (van der Linden et al.
2006). Background sound consisted of 70 dB white noise
pulse-alone trials of 105 dB and white noise bursts with
instant rise time. Prepulse trials consisted of either 75 or
85 dB white noise bursts preceding 105 dB pulses. Pulse
Psychopharmacology (2010) 207:559–569 561duration was 20 ms for prepulses and 40 ms for startle
pulses. Interstimulus interval was 100 ms, intertrial inter-
vals ranged between 8-12 s randomly. Each PPI measure-
ment started with 15 habituation trials (105 dB PA trials)
that were subsequently excluded from the analysis followed
by 12 trials of each type (105 dB, 85/105 dB, 75/105 dB) in
a pseudo-random order.
Data cleaning was performed off-line with MIDAC
software (test organizer-MIDAC polygraphy module, In-
strumentation Service, UMC St Radboud, Nijmegen, The
Netherlands), with a response window from 20-150 ms
after stimulus onset. Startle responses with an inconstant
baseline 20 ms before the stimulus with a response to the
prepulse or trials in which no startle response was detected
were excluded from further calculations.
The average amplitude of startle responses was calculated
for each trial type (105 dB, 75/105 dB and 85/105 dB) per
startle session (i.e., six sessions per treatment condition).
Percentage PPI was calculated for 75/105 dB and 85/105 dB
trials, per startle session, as follows: Mamplitude PA 
 
Mamplitude PPÞ= Mamplitude PA

  100%. A median split on
baseline PPI (both 75/105 dB and 85/105 dB) was used to
divide high and low baseline sensorimotor gaters (Bitsios et
al. 2005; Talledo et al. 2009a).
Procedure
Study mornings started at 8:30 a.m. with a standardized
light breakfast. Measurements were performed, once before
and five times after drug administration, starting with blood
sampling, followed by a 9-min startle session and,
consecutively, 10-min AX-CPT, each cycle lasting 20 min
(Fig. 1). Treatment conditions were 10 to 25 days apart.
Data analysis
Statistical Package for the Social Sciences (version 16.0)
under Windows was used for statistical analysis, with
α set at.05 (two-sided). The effect of APO on GH,
performance on the CPT-AX, and acoustic startle was
analyzed using GLM repeated measures analysis of
variance, with treatment (APO s.l., APO s.c., and placebo)
and time (baseline, T1, T2, T3, T4, and T5) as within-
subject factors. Scores on each outcome measure at
baseline were used to divide subjects by median split into
low and high performers so that we could examine the
effect of APO on these two groups for each outcome
measure a with group as a between-subject factor. In order
to control for a learning effect over the different sessions,
order was entered as a between-subjects factor in the
analysis of the AX-CPT. Since both the factors, time and
treatment, have two or more degrees of freedom,
Greenhouse-Geisser correction was used, epsilon values
and adjusted p values are reported.
In order to identify the specific time points with the
largest effect of APO, simple contrasts to baseline were
analyzed post hoc, only when the omnibus test showed
a significant interaction effect. To assess the relation
between baseline task performance on the AX-CPT and
baseline PPI, we computed Pearson's correlation between
speed and accuracy on the AX-CPT and PPI on 75/105 and
85/105 dB.
Individual curves of APO levels in the first and second
compartment were fitted in a previously validated algorithm
in MW/Pharm, a software package developed to study the
clinical effect of APO, e.g., in patients suffering from
Parkinson's disease (Mediware, version 3.60; Hofstee et al.
1994;N e e fe ta l .1994; Neef and van Laar 1999).
Individual fits were based on plasma APO levels, individ-
ual pharmacokinetic parameters (volume of distribution,
rate constants for elimination and intercompartmental
exchange, renal function, and body mass index), and
population kinetics. We computed Pearson's correlations
between the central outcome measures and time-locked
APO levels both in the first and second compartment
(plasma and CSF).
DRUG ADMINISTRATION (S.L. +S.C.) 
6x20 min.
 T0      T1              T2          T3      T4             T5 
(baseline) (10 min)      (30min)      (50min)       (70min)      (90min) 
APO
+ GH 
PPI
AX-
cpt
APO 
+ GH 
PPI
AX-
cpt
APO+
GH
PPI
AX-
cpt
APO
+ GH
PPI
AX-
cpt
APO 
+ GH 
PPI
AX-
cpt
APO
+ GH
PPI
AX-
cpt
Fig. 1 Outline of study days
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Plasma apomorphine and growth hormone levels
Both s.c.- and s.l.-administered APO resulted in detectable
plasma APO levels (Fig. 2). GH levels increased after
administration of APO, see Table 1 and Fig. 3 (F (10, 12)=
8.4, p<.001). PosthocanalysisshowedthattheeffectofAPO
wasmainlyat50minafters.c.administration(F(1,12)=18.3,
p=.001).
AX continuous performance task
Baseline task performance did not differ between treatments
(commission errors: F (2, 14)=0.6, p=.547; reaction time: F
(2, 14) <.01, p=.977). There was no effect of order on task
performance (F (3.3, 14)=.6, p=.611). There was no
difference in age or APO levels between the median split
groups (see Supplementary Table 1a). The percentage
commission errors increased after APO, particularly in
subjects with more error responses at baseline, see Table 1
and Fig. 4a (F (3.2, 14)=3.5, p=.030). Mean reaction time
on AX-trials increased after APO in subjects with slow
baseline responses, see Table 1 and Fig. 4b (F (4.2, 14)=
2.9, p=.030).
Post hoc analysis showed that the effect of APO on both
error percentage and reaction time was mainly at 40 min
after s.c. administration (error percentage: F (1, 14)=38.1,
p<.001, reaction time: F (1, 14)=21.6, p=.001).
0 1 2 3 4 5
0.0
0.5
1.0
1.5
2.0
plasma APO 2mg s.l.
plasma APO 0.005mg/kg s.c.
brain APO 0.005mg/kg
brain APO 2mg s.l.
A
P
O
 
(
U
/
l
)
Fig. 2 Results: plasma apomorphine (APO) concentration and APO
levels as estimated in the second compartment after oral (2 mg) and
sublingual (0.005 mg/kg) administration
Outcome measure Mean at baseline (SD) F-Statistic (df) ε-value p value
GH NA
-Time 13.4 (1.8, 12) .36 <.001
-Treatment 10.9 (1.7, 12) .87 .001
-Time*treatment 8.4 (2.7, 12) .27 <.001
CPT-AX, reaction time (msec) 347.91 ms (66.61)
-Time 2.1 (3.3, 14) .67 .107
-Treatment 2.7 (1.9, 14) .96 .090
-Time*treatment 1.7 (4.2, 14) .42 .157
-Time*treatment*baseline 2.9 (4.2, 14) .030
CPT-AX, commission errors (%) 4.8% (5.4)
-Time 1.0 (3.3, 14) .67 .399
-Treatment 0.4 (1.4, 14) .71 .580
-Time*treatment 0.5 (3.2, 14) .32 .675
-Time*treatment*baseline 3.5 (3.2, 14) .030
PPI 75/105 dB (%) 9.7% (22.6)
-Time 1.1 (3.7,14) .73 .381
-Treatment 2.2 (1.6,14) .78 .143
-Time*treatment 1.7 (5.0,14) .50 .161
-Time*treatment*baseline 2.8 (5.0,14) .024
PPI 85/105 dB (%) 22.2% (24.6)
-Time 2.5 (3.5, 14) .70 .040
-Treatment 3.5 (1.5,14) .75 .050
-Time*treatment 1.5 (4.9, 14) .49 .154
-Time*treatment*baseline 1.4 (4.9, 14) .182
Table 1 Results: baseline val-
ues and effect of treatment with
apomorphine (APO) on plasma
growth hormone (GH) levels,
performance on the AX-
continuous performance task
(AX-CPT), and prepulse inhibi-
tion (PPI)
Time main effect of time, treat-
ment main effect of treatment,
Time*treatment time by treat-
ment interaction effect, Time*-
treatment*baseline time by
treatment by baseline perfor-
mance interaction effect
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The number of excluded trials increased between baseline
and T5; from 13% to 26% for 75/105 dB (F (5, 14)=4.7,
p=.001), from 35% to 48% 105 dB (F (5, 14)=4.8,
p=.001), and from 24% to 32% 85/105 dB (F (5, 14)=
3.0, p=.018). This is mainly caused by an increase in the
number of non responses. The number of excluded trials
did not differ over the three drug conditions (105 dB trials:
F (10, 14)=1.1, p=.331, 75/105 dB trials: F (10, 14)=0.5,
p=.853, 85/105 dB trials: F (10, 14)=0.5, p=.900)
indicating no difference in habituation to the startle
stimulus over all treatment conditions. For the results of
the analysis on startle amplitudes (see Supplementary
Table 2 and Supplementary Figs. 1a–c).
Baseline PPI did not differ between treatments (PPI 75/
105 dB: F (2, 14)=0.4, p=.686, PPI 85/105 dB: F (2, 14)<
0.1, p=.911). There was no difference in age or APO levels
between the median split groups (see Supplementary
Table 1b). PPI decreased after administration of APO for
high-intensity prepulse trials (85/105 dB), see Table 1 and
Fig. 5a (F (1.5, 14)=3.5, p=.050). Baseline PPI did not
modulate the effect of APO on PPI in high-intensity
prepulse trials (F (4.9, 14)=1.4, p=.182). PPI increased
after administration of APO for low intensity prepulse trials
(75/105 dB) in subjects with low baseline PPI, see Table 1
and Fig. 5b (F (5.0, 14)=2.8, p=.024).
Post hoc analysis showed that the effect of APO on PPI
was mainly at 30 min after s.c. administration (85/105 dB:
F (1, 14)=6.0, p=.030; 75/105 dB: F (1, 14)=10.1,
p=.008).
Baseline PPI levels for low intensity prepulse trials were
inversely correlated with baseline accuracy on task perfor-
mance (75/105 dB: R=−.59, p=.021).
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Fig. 3 Results: plasma growth hormone levels before and after
sublingual (2 mg) and subcutaneous (0.005 mg/kg) administration of
apomorphine (APO)
a) Percentage commission errors on CPT-AX, by baseline task performance. 
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b) Reaction time on CPT-AX, by baseline task performance. 
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Fig. 4 Results: performance on AX-continuous performance task
(CPT-AX) before and after sublingual (2 mg) and subcutaneous
(0.005 mg/kg) administration of apomorphine (APO). a Percentage
commission errors on CPT-AX by baseline task performance. b
Reaction time on CPT-AX by baseline task performance
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The effect of APO on the outcome measures showed close
resemblance with the kinetics of APO (Fig. 2, 3, 4, 5). The
relation between APO levels and the observed effects could
best be modeled using S-curves (Fig. 6). Central measures
correlated best with APO levels in the second compartment
after s.c. administration, GH levels, and accuracy on the
AX-CPT in particular (Table 2).
Adverse events
Nausea was reported by five participants, between 10 and
40 min, only after s.c. administration of APO. Yawning and
weariness were reported in all conditions (placebo: seven
participants, APO s.l. ten participants, and APO s.c. 12
participants).
Discussion
Administration of the direct dopamine receptor agonist
APO to healthy individuals resulted in increased plasma
GH levels and disrupted performance on the AX-CPT as
predicted. APO improved PPI in prepulse trials of low
intensity (75/105 dB) in subjects with poor baseline
sensorimotor gating and disrupted PPI in high-intensity
prepulse trials (85/105 dB).
Elevated levels of plasma GH after administration of
APO are in line with previous studies that have shown GH
responses after comparable doses of APO in healthy
controls and patients suffering from schizophrenia, major
depression, and alcohol dependence (Schmidt et al. 2001).
The dose of APO currently administered appears to be
sufficient to stimulate central dopamine receptors.
The observed deterioration in cognitive performance
after APO is in line with other studies, showing decreased
cognitive performance after administration of APO and the
dopamine agonist pramipexole (Hamidovic et al. 2008;
Schellekens et al. 2009). Since dopamine receptors in the
prefrontal cortex (PFC) are located both at the presynaptic
and postsynaptic neuron, one could speculate that the
disruptive effect on cognitive performance is caused by
decreased dopamine functioning after stimulation of pre-
synaptic dopamine receptors or excessive dopamine func-
tioning after stimulation of postsynaptic dopamine
receptors (al-Tikriti et al. 1992; Wang and Pickel 2002).
In contrast with the hypotheses, participants with poor
baseline cognitive performance were most sensitive to the
deteriorating effects of APO on cognitive performance.
That individuals with presumed lower levels of prefrontal
dopamine functioning are more sensitive to the detrimental
effects of APO on cognitive performance suggests that
stimulation of presynaptic dopamine receptors, and subse-
quently reduced dopamine neurotransmission in the PFC is
involved. Further studies are needed to explore the
a) percentage PPI on 75dB prepulse trials, by high vs. low baseline levels of PPI.
1 2 3 4 5
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b) percentage PPI on 85dB prepulse trials. 
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Fig. 5 Results: percentage pre-
pulse inhibition (PPI) before and
after sublingual (2 mg) and
subcutaneous (0.005 mg/kg)
administration of apomorphine
(APO) on 75 dB and 85 dB
prepulse trials. a Percentage PPI
on 75 dB prepulse trials by high
vs. low baseline levels of PPI.
b Percentage PPI on 85 dB
prepulse trials
Psychopharmacology (2010) 207:559–569 565mechanisms underlying the effect of APO on cognitive
performance.
The observation of PPI disruption in high-intensity
prepulse trials after administration of APO, versus PPI
enhancement in low intensity prepulse trials, is in line with
previous findings with the dopamine agonists pergolide and
4-propyl-9-hydroxynaphthoxazine in rats (Martin-Iverson
and Else 2000; Swerdlow et al. 2001a, b). This paradoxical
finding has been hypothesized to result from either agonist
action on dopamine receptors located pre and post
synaptically, or at different parts in the startle neuro-
circuitry, or from agonist action on different neurochemical
subclasses of dopamine receptors, e.g., D3 and D4 (Martin-
Iverson and Else 2000; Swerdlow et al. 2001b).
Although dopamine receptors are located in several
different brain areas, there is substantial evidence from
preclinical research suggesting that the final pathway in the
disruptive effect of APO on PPI is dependent on stimulation
of dopamine receptors in the nucleus accumbens. Local
application of dopamine agonists in the nucleus accumbens,
but not in the neostriatum or the orbitofrontal cortex,
reduces PPI (Swerdlow et al. 1992; Wan et al. 1994).
Interestingly, within the prefrontal cortex, dopamine antag-
onists rather than agonists appear to decrease PPI
Table 2 Mean correlations between central outcome measures (plasma GH levels and performance on the AX-continuous performance task
(CPT-AX)) and apomorphine (APO) levels in plasma as calculated in the second compartment
GH, mean R (SD) AX-CPT, mean R (SD) reaction time errors PPI, mean R (SD) 75/105dB 85/105dB
APO 0.005 mg/kg s.c. N=8 N=9 N=9 N=9 N=9
1st compartment 0.20 (0.30) 0.41 (0.48) 0.58 (0.37) .289 (.25) −.175 (.44)
2nd compartment 0.58 (0.20) 0.45 (0.44) 0.58 (0.37) .282 (.35) −.178 (.39)
APO 2 mg s.l. N=5 N=5 N=5 N=5 N=5
1st compartment 0.01 (0.27) 0.46 (0.43) 0.33 (0.37) .074 (.41) −.192 (.33)
2nd compartment 0.30 (0.41) 0.43 (0.43) 0.46 (0.36) .137 (.22) −.373 (.32)
a) GH after 0.005mg/kg APO s.c.    
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Fig. 6 Results: relation between
apomorphine (APO) levels in
the first and second compart-
ment (blood and brain) and
time-locked plasma growth hor-
mone (GH) levels and error
percentage on the AX-
continuous performance task
(AX-CPT). a GH after
0.005 mg/kg APO s.c. b Error
percentage on AX-CPT after
0.005 mg/kg APO s.l.
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importantly, Swerdlow and colleagues also showed that the
PPI disruptive effect of systemically applied dopamine
agonists can be blocked by blocking dopamine transmission
in the nucleus accumbens (Swerdlow et al. 1990). These
data suggest that the effects of dopamine agonists on PPI
are predominantly mediated via the mesolimbic, nucleus
accumbens, and dopamine receptors. However, it cannot be
ruled out that the disruptive effect of APO on PPI may be
mediated by dopamine receptors in the medial prefrontal
cortex (Broersen et al. 1999; Lacroix et al. 2000).
At low prepulse intensities, APO-improved sensorimotor
gating in participants with suboptimal baseline levels of PPI
with presumed suboptimal mesolimbic dopamine function-
ing. This suggests that stimulation of postsynaptic dopa-
mine receptors and subsequently increased mesolimbic
dopamine neurotransmission is involved. In contrast,
baseline levels of PPI did not modify the response to
APO in high-intensity prepulse trials. PPI on high-intensity
prepulse trials is rather robust and likely less sensitive to the
effect of baseline PPI on APO sensitivity. Yet, at low
prepulse intensities, PPI may be dependent on a more
narrow optimum of mesolimbic dopamine functioning.
The observed negative correlation between baseline
cognitive performance and baseline PPI on low intensity
prepulse trials supports a previously suggested reciprocal
relation between prefrontal and subcortical dopamine
neurotransmission (Kellendonk et al. 2006; Wilkinson
1997). Participants with high baseline cognitive perfor-
mance, i.e., presumed optimal prefrontal dopamine func-
tioning showed impaired levels of sensorimotor gating, i.e.,
presumed suboptimal mesolimbic dopamine functioning.
Moreover, subjects sensitive to deteriorating effects of APO
on cognitive performance appeared to be less sensitive to
the PPI enhancing effects of APO. This again supports the
idea that whereas cognitive performance is more related to
cortical dopaminergic systems, PPI is more mediated via
mesolimbic dopaminergic systems.
Yet, it has previously been suggested that sensorimotor
gating is a pre-attentional function, important for the
integrity of higher order cognitive processes (Braff and
Geyer 1990). Previous studies have indeed shown levels of
PPI to correlate with attention and planning ability (Bitsios
and Giakoumaki 2005; Csomor et al. 2008; Giakoumaki
et al. 2006). These findings merit further investigation with
respect to the relation between sensorimotor gating and
higher order cognitive processes.
Several additional issues regarding PPI need to be
considered. First, the number of excluded startle trials in
this study (20%) is high compared to literature (5%)
(Bitsios et al. 2005; Braff et al. 1992; Liechti et al. 2001;
van der Linden et al. 2006). Moreover, the number of
excluded trials increased over consecutive startle sessions.
This may result from both habituation and weariness of the
participants due to repeated measurement sessions. Though
there was no effect of treatment on the number of excluded
trials, habituation effects may have influenced the observed
effects of APO on PPI. Importantly, we used a low dose of
APO (0.005 mg/kg s.c. or 2 mg s.l.) compared to animal
literature (e.g., 0.5 mg/kg). Direct translation of the current
findings to animal findings is, therefore, limited.
The effect of APO on the central outcome measures
closely follows the kinetics of APO. In line with our
hypotheses, we found the best correlation between central
outcome measures and calculated APO levels in the second
compartment (CSF) after s.c. administration. APO levels in
the second compartment show an S-curve relation with
central outcome measures, whereas plasma APO concen-
trations (first compartment) show a poor correlation due to a
large counter-clock hysteresis curve. The use of two-
compartmental pharmacokinetic/pharmacodynamic (PK/PD)
modeling may provide further insight in true pharmacody-
namic differences in dopamine receptor sensitivity between
groups taking into account pharmacokinetic differences.
Since correlation coefficients were rather low, factors other
than APO levels may contribute to the observed changes in
central outcome measures like weariness, motivational
decline, habituation to the acoustic startle, and a learning
effect on the AX-CPT. In addition, PK/PD analyses were
based on a limited number of participants. Future studies are
needed to confirm the current findings.
Conclusions
The apomorphine challenge test appears a useful tool to
assess dopamine receptor functioning at the level of the
forebrain. Baseline performance modulated the effect of
APO on task performance and PPI. This may be explained
by the hypothesized inverted U-shape relation between
prefrontal dopamine functioning and cognitive performance
and mesolimbic dopamine functioning and sensorimotor
gating. The current findings also suggest a reciprocal
relation between prefrontal and mesolimbic dopamine
functioning.
More studies on the relation between the central effects
of APO and levels of APO in the CSF are needed. Future
APO challenge studies into dopamine dysfunctioning in
neuropsychiatric disorders preferably use multiple outcome
measures after s.c. administration.
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